Live Breaking News & Updates on Grants Fast Track Designation

U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this DesignationGlobal Phase 3 Trial in Primary Choroidal Melanoma on Track to Begin Dosing in 1H 2023BOSTON (B. ....

United States , Matthew Deyoung , Alex Dasalla , Los Pinos , Belzupacap Sarotalocan , Oncology Division , Aura Biosciences Inc , Drug Administration , Exchange Commission , Corporate Communications , Macula Society , Grants Fast Track Designation , Choroidal Metastasis , Second Ocular Oncology Indication , Primary Choroidal Melanoma , Begin Dosing , Aura Biosciences , Annual Meeting , Elisabet De Los Pinos , Chief Executive Officer , Fast Track Designation , Cadmus Rich , Chief Medical Officer , Investigational Drug , Gross Proceeds , Oversubscribed Follow On Public ,